The Importance of Care Coordination for Patients with Psoriatic ArthritisPremiere Date: Monday, June 22, 2020
This activity offers CE credit for:%>
- Physicians (CME)
- Pharmacists (ACPE)
- ABIM (MOC)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Wednesday, June 22, 2022
Note: Credit Is No Longer Available
|Joel M. Gelfand, MD, MSCE
Professor of Dermatology and Epidemiology
Vice Chair of Clinical Research
Medical Director, Dermatology Clinical Studies Unit
Director, Psoriasis and Phototherapy Treatment Center
University of Pennsylvania Perelman School of Medicine
Psoriasis (PsO) and psoriatic arthritis (PsA) are complex disorders that require coordinated care between dermatologists and rheumatologists. Challenges to effective management include a lack of education of patients and health care providers (HCPs), suboptimal communication, and clinicians' lack of a holistic treatment approach.
The third episode of this BriefCase series on challenging cases in PsO and PsA features a physician-patient office scenario video on educating the patient and strategies to coordinate care between specialists, as well as between specialists and primary care, with a goal of optimizing patient outcomes.
At the end of this CE activity, participants should be able to:
- Coordinate care for patients with PsA to optimize outcomes and quality of life (QoL).
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Summarize coordination of care for patients with PsA to optimize outcomes and QoL.
Supported by educational grants from Celgene and Novartis Pharmaceuticals Corporation.
Dermatologists, primary care physicians, nurse practitioners, physician assistants, and pharmacists
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 0.25 contact hours (0.025 CEUs) Universal Activity Number:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Note to PAs: PAs may claim a maximum of .25 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Gelfand reports that he receives grants from AbbVie Inc.; Boehringer Ingelheim; Celgene Corporation; Janssen Biologics, Inc.; Novartis Corporation; Ortho Dermatologics; and Pfizer Inc. He is a consultant for Boehringer Ingelheim; Bristol-Myers Squibb Company; Janssen Biologics, Inc.; NeuroDerm Data and Safety Monitoring Board (DSMB); Novartis Corporation; Pfizer Inc.; Sun Pharmaceutical Industries; and UCB Data and Safety Monitoring Board (DSMB). He receives other financial or material support as a co-patent holder of resiquimod for treatment of cutaneous T-cell lymphoma; and as Deputy Editor for the Journal of Investigative Dermatology, receiving honoraria from the Society for Investigative Dermatology.
Dr. Helfand (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Poshala Tish Aluwihare, PhD (planning committee) has no disclosures to report.
Susan Perry (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
CME Outfitters, LLC and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).